l-n-(n-hydroxy-2-isobutylsuccinamoyl)seryl-l-valine has been researched along with Glial Cell Tumors in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Sugisaki, Y; Takahashi, H; Teramoto, A; Watanabe, K; Yoshida, D | 1 |
| Noha, M; Teramoto, A; Watanabe, K; Yoshida, D | 1 |
2 other study(ies) available for l-n-(n-hydroxy-2-isobutylsuccinamoyl)seryl-l-valine and Glial Cell Tumors
| Article | Year |
|---|---|
Apoptotic induction by BE16627B on human malignant glioma cell lines by an anti-matrix metalloproteinase agent.
Topics: Apoptosis; Cell Line, Tumor; Dipeptides; DNA Fragmentation; Dose-Response Relationship, Drug; Electrophoresis, Agar Gel; Enzyme Inhibitors; Glioma; Humans; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Microscopy, Electron; Succinates | 2003 |
Suppression of matrix metalloproteinase-2 and -9 mediated invasiveness by a novel matrix metalloproteinase inhibitor, BE16627B.
Topics: Antineoplastic Agents; Collagen Type IV; Coloring Agents; Dipeptides; Glioma; Humans; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Neoplasm Invasiveness; Protease Inhibitors; Succinates; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 2001 |